niacinamide has been researched along with Schizophrenia in 43 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Schizophrenia: A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Increased concentrations of kynurenine pathway metabolites have been reported by several groups for disorders involving psychosis, including schizophrenia and bipolar disorder." | 7.74 | Alterations in kynurenine precursor and product levels in schizophrenia and bipolar disorder. ( Cwik, M; Llenos, IC; Miller, CL; Walkup, J; Weis, S, 2008) |
| "The effectiveness of combined phenazepam, lithium, haloperidol and metabolic drugs (alpha-tocopherol, pyridoxal phosphate, nicotinamide) treatment of patients with slow progredient schizophrenia is analyzed." | 7.67 | [Comparative effectiveness of the combined use of fenazepam, haloperidol, lithium and metabolic preparations in treating the psychopathologic disorders with obsessions in slowly progressive schizophrenia]. ( Kadysheva, NM; Kryzhanovskiĭ, GN; Mokhovikov, AN; Mosketi, KV, 1988) |
| "Increased concentrations of kynurenine pathway metabolites have been reported by several groups for disorders involving psychosis, including schizophrenia and bipolar disorder." | 3.74 | Alterations in kynurenine precursor and product levels in schizophrenia and bipolar disorder. ( Cwik, M; Llenos, IC; Miller, CL; Walkup, J; Weis, S, 2008) |
| "The effectiveness of combined phenazepam, lithium, haloperidol and metabolic drugs (alpha-tocopherol, pyridoxal phosphate, nicotinamide) treatment of patients with slow progredient schizophrenia is analyzed." | 3.67 | [Comparative effectiveness of the combined use of fenazepam, haloperidol, lithium and metabolic preparations in treating the psychopathologic disorders with obsessions in slowly progressive schizophrenia]. ( Kadysheva, NM; Kryzhanovskiĭ, GN; Mokhovikov, AN; Mosketi, KV, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 35 (81.40) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (6.98) | 29.6817 |
| 2010's | 2 (4.65) | 24.3611 |
| 2020's | 3 (6.98) | 2.80 |
| Authors | Studies |
|---|---|
| Brown, J | 2 |
| Iacovelli, L | 1 |
| Di Cicco, G | 1 |
| Grayson, B | 2 |
| Rimmer, L | 1 |
| Fletcher, J | 1 |
| Neill, JC | 2 |
| Wall, MJ | 2 |
| Ngomba, RT | 2 |
| Harte, M | 2 |
| Huang, H | 1 |
| Zheng, S | 1 |
| Chen, M | 1 |
| Xie, L | 1 |
| Li, Z | 1 |
| Guo, M | 1 |
| Wang, J | 1 |
| Lu, M | 1 |
| Zhu, X | 1 |
| Koványi, B | 1 |
| Csölle, C | 1 |
| Calovi, S | 1 |
| Hanuska, A | 1 |
| Kató, E | 1 |
| Köles, L | 1 |
| Bhattacharya, A | 1 |
| Haller, J | 1 |
| Sperlágh, B | 1 |
| Hoffer, A | 4 |
| Prousky, J | 1 |
| Seybolt, SE | 1 |
| BELSANTI, R | 1 |
| ASHBY, WR | 1 |
| COLLINS, GH | 1 |
| BASSETT, M | 1 |
| DENSON, R | 1 |
| HEYMAN, JJ | 2 |
| HALPERN, S | 1 |
| MERLIS, S | 1 |
| GAMNA, G | 1 |
| FORNARI, U | 1 |
| Miller, CL | 1 |
| Llenos, IC | 1 |
| Cwik, M | 1 |
| Walkup, J | 1 |
| Weis, S | 1 |
| Mys'ko, GN | 2 |
| Mileikovskii, IuA | 1 |
| Mrochek, JE | 1 |
| Jolley, RL | 1 |
| Young, DS | 1 |
| Turner, WJ | 1 |
| Cazzullo, CL | 1 |
| Sacchetti, E | 1 |
| Smeraldi, E | 1 |
| Deutsch, M | 1 |
| Ananth, JV | 2 |
| Ban, TA | 2 |
| Molcan, J | 1 |
| Rakús, A | 1 |
| Motýlová, A | 1 |
| Kadysheva, NM | 1 |
| Mokhovikov, AN | 1 |
| Mosketi, KV | 1 |
| Kryzhanovskiĭ, GN | 1 |
| Smythies, JR | 1 |
| Alvarez, WC | 1 |
| Spaide, J | 1 |
| Tanimukai, H | 1 |
| Ginther, R | 1 |
| Bueno, J | 1 |
| Himwich, HE | 1 |
| Neumann, H | 1 |
| Rappaport, M | 1 |
| Heninger, GR | 1 |
| Bowers, MB | 1 |
| Gentili, C | 1 |
| Borghesi, E | 1 |
| Kanig, K | 1 |
| Oesterle, W | 1 |
| Newbold, HL | 1 |
| Mosher, LR | 1 |
| Kety, SS | 1 |
| Vallely, JF | 1 |
| Lovegrove, TD | 1 |
| Hobbs, GE | 1 |
| Vacaflor, L | 1 |
| Kekhwa, G | 1 |
| Sterlin, C | 1 |
| Baker, GA | 1 |
| Stone, WN | 1 |
| Hofling, CK | 1 |
| Winslow, WW | 1 |
| Pauling, L | 1 |
| McGrath, SD | 1 |
| Altus, MS | 1 |
2 reviews available for niacinamide and Schizophrenia
| Article | Year |
|---|---|
[Biochemical treatment possibilities in psychoses].
Topics: Amino Acids; Ascorbic Acid; Dihydroxyphenylalanine; Humans; Methionine; Niacinamide; Nicotinic Acids | 1969 |
Dietary factors and schizophrenia.
Topics: Ascorbic Acid; Diet; Edible Grain; Humans; Methionine; Niacinamide; Nutritional Physiological Phenom | 1970 |
7 trials available for niacinamide and Schizophrenia
| Article | Year |
|---|---|
Nicotinic acid in the treatment of chronic hospitalized schizophrenic patients: a placebo-controlled clinical study.
Topics: Adult; Chronic Disease; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation; Female; Huma | 1977 |
The effect of nicotinic acid on the frequency and duration of re-hospitalization of schizophrenic patients; a controlled comparison study.
Topics: Clinical Trials as Topic; Follow-Up Studies; Hospitalization; Humans; Niacinamide; Nicotinic Acids; | 1966 |
Nicotinic acid and nicotinamide in the treatment of chronic schizophrenia.
Topics: Chronic Disease; Clinical Trials as Topic; Evaluation Studies as Topic; Humans; Niacinamide; Nicotin | 1971 |
Nicotinic acid in the treatment of newly admitted schizophrenic patients: a placebo-controlled study.
Topics: Adolescent; Adult; Chlorpromazine; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Niac | 1972 |
Nicotinic acid in the treatment of schizophrenia.
Topics: Acute Disease; Blood Glucose; Chronic Disease; Clinical Trials as Topic; Humans; Hyperbilirubinemia; | 1973 |
Drug therapy.
Topics: Adolescent; Adult; Antidepressive Agents; Antiparkinson Agents; Butyrophenones; Cannabis; Chlorproth | 1971 |
Letter: nicotinamide treatment: an addendum.
Topics: Electroconvulsive Therapy; Humans; Niacinamide; Placebos; Schizophrenia; Time Factors | 1974 |
34 other studies available for niacinamide and Schizophrenia
| Article | Year |
|---|---|
The comparative effects of mGlu5 receptor positive allosteric modulators VU0409551 and VU0360172 on cognitive deficits and signalling in the sub-chronic PCP rat model for schizophrenia.
Topics: Allosteric Regulation; Animals; Cognition; Niacinamide; Oxazoles; Phencyclidine; Proto-Oncogene Prot | 2022 |
Oscillatory Deficits in the Sub-Chronic PCP Rat Model for Schizophrenia Are Reversed by mGlu5 Receptor-Positive Allosteric Modulators VU0409551 and VU0360172.
Topics: Animals; Niacinamide; Prefrontal Cortex; Rats; Schizophrenia; Signal Transduction | 2023 |
The potential of the P2X7 receptor as a therapeutic target in a sub-chronic PCP-induced rodent model of schizophrenia.
Topics: Animals; Animals, Newborn; Drug Delivery Systems; Hallucinogens; Injections, Subcutaneous; Male; Mic | 2021 |
The role of P2X7 receptors in a rodent PCP-induced schizophrenia model.
Topics: Animals; Behavior, Animal; Cerebral Cortex; Mice; Mice, Knockout; Niacinamide; Phencyclidine; Pipera | 2016 |
Successful treatment of schizophrenia requires optimal daily doses of vitamin B3.
Topics: Adrenochrome; Humans; Niacinamide; Schizophrenia; Schizophrenic Psychology; Vitamin B Complex | 2008 |
Is it time to reassess alpha lipoic acid and niacinamide therapy in schizophrenia?
Topics: Antioxidants; Dopamine; Glutathione; Glutathione Disulfide; Humans; Mitochondria; Mitochondrial Memb | 2010 |
Niacinamide. Monograph.
Topics: Acute Disease; Animals; Anticonvulsants; Diabetes Mellitus, Type 1; Drug Interactions; Humans; Niaci | 2002 |
[Treatment of chronic schizophrenia by a combination of electroshock, pantothenic acid and nicotinamide].
Topics: Convulsive Therapy; Electroconvulsive Therapy; Electroshock; Niacin; Niacinamide; Nicotinic Acids; P | 1954 |
The effects of nicotinic acid, nicotinamide, and placebo on the chronic schizophrenic.
Topics: Humans; Niacin; Niacinamide; Nicotinic Acids; Schizophrenia | 1960 |
Nicotinamide in the treatment of schizophrenia.
Topics: Humans; Niacin; Niacinamide; Nicotinic Acids; Schizophrenia | 1962 |
THE USE OF NICOTINAMIDE TEST DOSE IN THE ASSESSMENT OF PSYCHOTROPIC DRUGS IN SCHIZOPHRENIC PATIENTS.
Topics: Biomedical Research; Chlordiazepoxide; Chlorpromazine; Humans; Imipramine; Lactose; Niacin; Niacinam | 1964 |
NICOTINAMIDE METABOLISM IN SCHIZOPHRENICS, DRUG ADDICTS, AND NORMALS: THE EFFECT OF PSYCHOTROPIC DRUGS AND HORMONES.
Topics: Adrenocorticotropic Hormone; Antidepressive Agents; Drug Users; Estradiol; Hydrocortisone; Lysergic | 1964 |
[ATTEMPTS OF TREATMENT OF SCHIZOPHRENIA WITH ANTIMETABOLITES].
Topics: Antimetabolites; Drug Therapy; Humans; Niacin; Niacinamide; Schizophrenia; Triethylenemelamine | 1964 |
Alterations in kynurenine precursor and product levels in schizophrenia and bipolar disorder.
Topics: 3-Hydroxyanthranilic Acid; Adult; Biomarkers; Bipolar Disorder; Brain; Chromatography, High Pressure | 2008 |
[Determination of methylnicotinamide in the blood and urine as a means of controlling neuroleptic treatment effectiveness].
Topics: Antipsychotic Agents; Drug Evaluation; Humans; Mental Disorders; Niacinamide; Schizophrenia | 1982 |
[Several indices of the methylation process in schizophrenic patients].
Topics: Adult; Antipsychotic Agents; Automatism; Catechol O-Methyltransferase; Depression; Female; Hallucina | 1977 |
[Excretion of catecholamines and tryptophan derivatives in schizophrenia].
Topics: Adolescent; Adult; Biogenic Amines; Dihydroxyphenylalanine; Dopamine; Epinephrine; Female; Humans; H | 1976 |
Metabolic response of humans to ingestion of nicotinic acid and nicotinamide.
Topics: Adult; Alcoholism; Computers; Heart Diseases; Humans; Kinetics; Male; Middle Aged; Niacinamide; Nico | 1976 |
N-methylnicotinamide excretion and affective disorders.
Topics: Adjustment Disorders; Adolescent; Adult; Bipolar Disorder; Depression; Female; Humans; Male; Middle | 1976 |
[Preliminary experiences with nicotinamide administration in schizophrenia (author's transl)].
Topics: Adult; Humans; Male; Niacinamide; Schizophrenia | 1978 |
[Comparative effectiveness of the combined use of fenazepam, haloperidol, lithium and metabolic preparations in treating the psychopathologic disorders with obsessions in slowly progressive schizophrenia].
Topics: Adolescent; Adult; Aged; alpha-Tocopherol; Anti-Anxiety Agents; Benzodiazepines; Benzodiazepinones; | 1988 |
Letter: Nicotinamide treatment of schizophrenia.
Topics: Acute Disease; Adult; Bipolar Disorder; Chronic Disease; Drug Evaluation; Female; Humans; Male; Niac | 1973 |
Use of nicotinic acid and/or nicotinamide in high doses to treat schizophrenia.
Topics: Humans; Niacinamide; Nicotinic Acids; Nursing; Schizophrenia | 1966 |
A chemical treatment for schizophrenia.
Topics: Adolescent; Aged; Child; Epinephrine; Female; Humans; Niacinamide; Nicotinic Acids; Schizophrenia | 1967 |
Schizophrenic behavior and urinary tryptophan metabolites associated with cysteine given with and without a monoamine oxidase inhibitor (tranylcypromine).
Topics: Adult; Catatonia; Creatine; Cysteine; Humans; Indoleacetic Acids; Male; Middle Aged; Niacinamide; Pa | 1967 |
[Clinical and pathophysiologic aspects of the therapy of schizophrenic psychotics with nicotinic acid amide].
Topics: Adult; Humans; Middle Aged; Niacinamide; Schizophrenia | 1967 |
Mental health research at a state hospital. An attempt at a balanced program.
Topics: Amantadine; Attitude of Health Personnel; Auditory Perception; Behavior Therapy; Computers; Conditio | 1968 |
Adverse effects of niacin in emergent psychosis.
Topics: Adult; Humans; Lysergic Acid Diethylamide; Male; Niacinamide; Nicotinic Acids; Psychoses, Substance- | 1968 |
[Remarks on the level of transmethylases in schizophrenic patients. In vitro assays].
Topics: Betaine; Humans; In Vitro Techniques; Methylation; Niacinamide; Schizophrenia | 1967 |
Niacin and the schizophrenic patient.
Topics: Diazepam; Edema; Gastrointestinal Diseases; Humans; Liver Function Tests; Mental Disorders; Niacinam | 1970 |
LSD-induced psychosis and vitamin B 3 .
Topics: Electroconvulsive Therapy; Humans; Lysergic Acid Diethylamide; Niacinamide; Psychoses, Substance-Ind | 1972 |
Letter: Effects of nutrition on schizophrenia.
Topics: Animals; Celiac Disease; Diet Therapy; Edible Grain; Glutens; Greece; Humans; Milk; Niacinamide; Nic | 1973 |
Letter: Dr. Pauling comments on the comments.
Topics: Drug Evaluation; Humans; Niacinamide; Nicotinic Acids; Schizophrenia; Vitamins | 1974 |
Letter: NAD and chronic schizophrenia.
Topics: Chronic Disease; Drug Evaluation; Drug Therapy, Combination; Humans; NAD; Niacinamide; Nicotinic Aci | 1974 |